LivaNova (NASDAQ:LIVN) Price Target Raised to $61.00

LivaNova (NASDAQ:LIVN - Free Report) had its price objective boosted by Robert W. Baird from $55.00 to $61.00 in a report issued on Thursday morning,Benzinga reports. Robert W. Baird currently has an outperform rating on the stock.

LIVN has been the topic of several other research reports. Mizuho lowered their target price on shares of LivaNova from $70.00 to $60.00 and set an "outperform" rating on the stock in a report on Wednesday, February 26th. Stifel Nicolaus lowered their price target on shares of LivaNova from $72.00 to $60.00 and set a "buy" rating on the stock in a report on Wednesday, February 26th. StockNews.com upgraded shares of LivaNova from a "buy" rating to a "strong-buy" rating in a research note on Tuesday, March 25th. Needham & Company LLC reiterated a "buy" rating and issued a $64.00 target price on shares of LivaNova in a research note on Monday, March 17th. Finally, Barclays dropped their target price on shares of LivaNova from $58.00 to $56.00 and set an "equal weight" rating for the company in a report on Friday, March 7th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, LivaNova currently has a consensus rating of "Moderate Buy" and an average price target of $59.17.

LivaNova Stock Down 1.3%

Shares of LivaNova stock traded down $0.59 during trading on Thursday, hitting $44.64. The company's stock had a trading volume of 352,649 shares, compared to its average volume of 639,368. The company has a market capitalization of $2.43 billion, a PE ratio of 106.29 and a beta of 0.84. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37. LivaNova has a 52 week low of $32.48 and a 52 week high of $63.57. The company has a fifty day simple moving average of $37.98 and a two-hundred day simple moving average of $45.04.

Institutional Trading of LivaNova

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Nordea Investment Management AB increased its stake in LivaNova by 22.2% in the 4th quarter. Nordea Investment Management AB now owns 68,711 shares of the company's stock valued at $3,188,000 after buying an additional 12,470 shares during the period. Diversified Trust Co boosted its holdings in LivaNova by 9.5% in the 4th quarter. Diversified Trust Co now owns 16,432 shares of the company's stock valued at $761,000 after purchasing an additional 1,425 shares during the period. Harbor Capital Advisors Inc. bought a new position in shares of LivaNova during the 4th quarter worth about $1,954,000. KBC Group NV lifted its holdings in shares of LivaNova by 130.5% during the 4th quarter. KBC Group NV now owns 99,928 shares of the company's stock worth $4,628,000 after acquiring an additional 56,580 shares during the period. Finally, Rhumbline Advisers boosted its position in LivaNova by 0.5% in the fourth quarter. Rhumbline Advisers now owns 177,938 shares of the company's stock valued at $8,240,000 after buying an additional 899 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.